1. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018 Subject(s): Antibodies, Bispecific -- therapeutic useAntibodies, Monoclonal -- therapeutic useHemophilia A -- drug therapyAntibodies, Bispecific -- adverse effectsAntibodies, Monoclonal -- adverse effectsCost-Benefit AnalysisTreatment OutcomeHumansUnited States
